Table 2.
Treatment characteristics (n=61).
| Median (IQR) or N (%) | |||
|---|---|---|---|
| First treatment | RT alone | 3 (4.9) | |
| Surgery + RT | 40 (65.6) | ||
| Chemotherapy + RT | 9 (14.8) | ||
| Surgery + chemotherapy + RT | 9 (14.8) | ||
| RT dose (Gy) | 64.0 (56.0–68.0) | ||
| Re-treatment | Re-RT alone | 4 (6.6) | |
| Surgery + re-RT | 13 (21.3) | ||
| Systemic therapy + re-RT | 27 (44.3) | ||
| Surgery + systemic therapy + re-RT | 17 (27.9) | ||
| Surgery | Both primary site + lymph node | 5 (16.7)* | |
| Only primary site | 17 (56.7)* | ||
| Only lymph node | 8 (26.7)* | ||
| R0 | 5 (16.7)* | ||
| R1 | 14 (46.7)* | ||
| R2 | 11 (36.7)* | ||
| Extracapsular extension | 8 (61.5)† | ||
| Chemotherapy | No indication | 4 (6.6) | |
| Indicated but not administered | 16 (26.2) | ||
| Age | 7 | ||
| Comorbidity | 4 | ||
| Patient refusal | 3 | ||
| Weight loss | 1 | ||
| Tumor progression | 1 | ||
| Early terminated | 17 (27.9) | ||
| Toxicity of chemotherapy | 11 | ||
| Deterioration of general condition |
2 | ||
| Tumor progression | 2 | ||
| Comorbidity | 1 | ||
| Weight loss | 1 | ||
| Administered as planned | 24 (39.3) | ||
| Systemic therapy agents | Cis-5FU | 13 (29.5)‡ | |
| Carbo-5FU | 14 (31.8)‡ | ||
| From Cis-5FU switch to Carbo-5FU | 12 (27.3)‡ | ||
| Cis | 2 (4.5)‡ | ||
| Cetuximab | 3 (6.8)‡ | ||
| Time interval between RT courses (months) | 23.6 (8.4–76.6) | ||
| Re-RT dose (Gy) | 60 (54.6–60.0) | ||
| Re-RT dose (Gy) | =60 | 42 (68.9) | |
| ≥50 and <60 | 10 (16.4) | ||
| <50, early terminated due to: | 9 (14.8) | ||
| Tumor progression | 4 | ||
| Comorbidity | 2 | ||
| Toxicity of chemotherapy | 2 | ||
| Weight loss | 1 | ||
| Cumulative lifetime dose (Gy) | 120.0 (116.0–126.0) | ||
| Overlap ≥50 Gy isodose (cm3)§ | 177.4 (109.7–262.2) | ||
| Overlap ≥60 Gy isodose (cm3)¦ | 39.8 (23.8–79.5) | ||
IQR, interquartile range; RT, radiotherapy; re-RT, re-irradiation; Cis-5FU, cisplatin plus fluorouracil; Carbo-5FU, carboplatin plus fluorouracil; Cis, cisplatin. * Percentage of postoperative patients (N=30). † Percentage of patients who underwent neck surgery (N=13). ‡ Percentage of those receiving systemic therapy (N=44). § Referred to patients with electronically available dose plans and who received a complete course of re-RT therapy (N=35). ¦ Referred to 23 patients in which an overlapping volume for the ≥ 60 Gy isodose was observed.